[{"orgOrder":0,"company":"Sarah K. Lynam MD","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Sarah K. Lynam MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sarah K. Lynam MD \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Sarah K. Lynam MD \/ Bayer AG"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase III","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Translational Research In Oncology \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Translational Research In Oncology \/ Bayer AG"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Merck & Co"},{"orgOrder":0,"company":"Ospedale Policlinico San Martino","sponsor":"Associazione Italiana per la Ricerca sul Cancro | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Ospedale Policlinico San Martino","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ospedale Policlinico San Martino \/ Associazione Italiana per la Ricerca sul Cancro | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Ospedale Policlinico San Martino \/ Associazione Italiana per la Ricerca sul Cancro | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Bayer AG"},{"orgOrder":0,"company":"Teclison","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirapazamine","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Teclison \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/ Merck & Co"},{"orgOrder":0,"company":"Beijing YouAn Hospital","sponsor":"Beijing Gene Key Life Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Induced Pluripotent Stem Cell Derived Natural Killer Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing YouAn Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing YouAn Hospital \/ Beijing Gene Key Life Technology","highestDevelopmentStatusID":"8","companyTruncated":"Beijing YouAn Hospital \/ Beijing Gene Key Life Technology"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"China Medical University, China","sponsor":"ImmVira","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"China Medical University, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"China Medical University, China \/ ImmVira","highestDevelopmentStatusID":"6","companyTruncated":"China Medical University, China \/ ImmVira"},{"orgOrder":0,"company":"Australasian Gastro-Intestinal Trials Group","sponsor":"Bayer AG | Bristol Myers Squibb | University of Sydney | Academic and Community Cancer Research United | Taiwanese Cooperative Oncology Group | Frankfurter Institut f\u00fcr Klinische Krebsforschung | National Cancer Center Hospital East | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase III","graph3":"Australasian Gastro-Intestinal Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Australasian Gastro-Intestinal Trials Group \/ Bayer AG | Bristol Myers Squibb | University of Sydney | Academic and Community Cancer Research United | Taiwanese Cooperative Oncology Group | Frankfurter Institut f\u00fcr Klinische Krebsforschung | National Cancer Center Hospital East | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Australasian Gastro-Intestinal Trials Group \/ Bayer AG | Bristol Myers Squibb | University of Sydney | Academic and Community Cancer Research United | Taiwanese Cooperative Oncology Group | Frankfurter Institut f\u00fcr Klinische Krebsforschung | National Cancer Center Hospital East | Syneos Health"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Bayer AG"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"National Cancer Institute | THERABIONIC INC.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wake Forest University Health Sciences \/ National Cancer Institute | THERABIONIC INC.","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ National Cancer Institute | THERABIONIC INC."},{"orgOrder":0,"company":"SC Liver Research Consortium, LLC","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"SC Liver Research Consortium, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SC Liver Research Consortium, LLC \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"SC Liver Research Consortium, LLC \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"CHA University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"CHA University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CHA University \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"CHA University \/ Bayer AG"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Istituto Oncologico Veneto","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Istituto Oncologico Veneto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Istituto Oncologico Veneto \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Istituto Oncologico Veneto \/ Bayer AG"},{"orgOrder":0,"company":"University of Miami","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Miami \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"GNT Biotech & Medicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GNT Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GNT Biotech & Medicals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GNT Biotech & Medicals \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Center Hospital East","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Center Hospital East","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Cancer Center Hospital East \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Center Hospital East \/ Bayer AG"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase I","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gustave Roussy \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Gustave Roussy \/ Bayer AG"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"18-F Fludeoxyglucose","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||C-C chemokine receptor type 5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bayer AG | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bayer AG | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bayer AG | Bristol Myers Squibb"},{"orgOrder":0,"company":"Gruppo Oncologico del Nord-Ovest","sponsor":"Bayer AG | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Gruppo Oncologico del Nord-Ovest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gruppo Oncologico del Nord-Ovest \/ Bayer AG | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Gruppo Oncologico del Nord-Ovest \/ Bayer AG | Amgen Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Xencor | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Xencor | Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Xencor | Bayer AG"},{"orgOrder":0,"company":"Ibrahim Halil Sahin","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Ibrahim Halil Sahin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ibrahim Halil Sahin \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Ibrahim Halil Sahin \/ Bayer AG"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Bayer AG"},{"orgOrder":0,"company":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"China Medical University, China","sponsor":"Beijing Bio-Targeting Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"BioTTT001","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"China Medical University, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hepatic Infusion","sponsorNew":"China Medical University, China \/ Beijing Bio-Targeting Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"China Medical University, China \/ Beijing Bio-Targeting Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Regorafenib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
